Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.50
Bid: 42.00
Ask: 45.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.143%)
Open: 43.50
High: 43.50
Low: 43.50
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AB Sugar Head of Innovation joins Frontier IP

17 Sep 2018 07:00

RNS Number : 8821A
Frontier IP Group plc
17 September 2018
 

 

RNS Reach 

AIM: FIPP

17 September 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Team Expansion - AB Sugar Head of Innovation Matthew White joins Frontier IP

 

 

Frontier IP, which specialises in commercialising university intellectual property, is delighted to announce that Matthew White, the Head of Innovation at AB Sugar, one of the world's largest sugar producers and a wholly-owned subsidiary of AB Foods, is joining the Group as Director of Commercialisation, in a non-board role.

 

Matthew has 23 years' experience in technology, product and service innovation, business development and marketing. As AB Sugar's Head of Innovation, he was responsible for defining strategy and managing a global innovation portfolio. The role involved working extensively with university partners on collaborative research programmes totalling over £20million.

 

Before joining AB Sugar, Matthew was Director of Consumer Products for international technology consulting and product development business Sagentia Limited, working across a wide range of sectors.

 

He started his career at Neotronics Scientific, one of the first companies to commercialise electronic odour sensing. He has a Natural Sciences degree majoring in Chemistry from the University of Cambridge.

 

 

Neil Crabb, Chief Executive of Frontier IP, said: "It is a real pleasure to welcome Matthew to the Frontier IP team. His superb range of skills and experience provide an excellent match for the work many of our portfolio companies are undertaking."

 

Matthew White, said: "It is fantastic to be joining everyone at Frontier IP. I am looking forward to using my network and experience to accelerate the commercialisation activities of our exciting portfolio."

 

 

ENQUIRIES

 

Frontier IP Group Plc

 

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

 

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

 

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRASFSFMLFASESU
Date   Source Headline
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.